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Abstract 
Many genetic diseases exhibit considerable epidemiological comorbidity and common 
symptoms, which provokes debate about the extent of their etiological overlap. The 
relationships between inherited diseases have often been studied in relation to the common 
genes or pathways involved. However, the sharing of disease-associated genes is not 
automatically indicative of similar molecular mechanisms because different mutations may 
affect different functional aspects of genes/proteins leading to unrelated pathological 
conditions. The rapid growth in the number of known disease-causing mutations in the Human 
Gene Mutation Database (HGMD) has allowed us to characterise disease genetic similarity (or 
disease-disease relationships) by ascertaining the extent to which identical genetic mutations 
are shared between diseases. Using this approach, we show that 41.6% of disease pairs in all 
possible pairs (42,083) exhibit a significantly sharing of mutations (P-value<0.05). These 
mutation-related disease pairs are in agreement with heritability-based disease-disease 
relations in 48 neurological and psychiatric disease pairs (Spearman’s correlation 
coefficient=0.50; P-value=3.4×10-5), and share over-expressed genes significantly more often 
2than unrelated disease pairs (1.5 to 1.8-fold higher; P-value ≤ 1.6×10-4). We further demonstrate 
the utility of mutation-related disease pairs in predicting novel mutations and improving the 
identification of individuals susceptible to Crohn’s disease. Moreover, the mutation-based 
disease network concurs closely with that based on phenotypes. In all these applications, 
disease-disease relations inferred from shared mutations perform significantly better than those 
derived from shared genes. This work highlights the potential for inferring disease-disease 
relationships at the mutational level.
Introduction 
The co-occurrence of apparently distinct diseases is frequently observed as clinical phenotypic 
overlaps between different genetic diseases. For example, an increased incidence of Attention 
Deficit Hyperactivity Disorder (ADHD) has been found in families with bipolar disorder 
(Faraone et al. 2012). Patients with Friedreich ataxia appear to be at increased risk of 
developing type 2 diabetes mellitus (Ristow 2004). Type I diabetes and celiac disease often co-
exist in populations because of seven common associated [HUIYING: what do you mean by 
‘associated’? GWAS?] loci (Smyth et al. 2008). Inflammatory bowel disease is known to be 
associated with an increased incidence of psychological disorders such as depression  
[HUIYING: major depressive disorder?] (Szigethy et al. 2015). Such co-occurrences are being 
increasingly discovered between disease pairs through the statistical analysis of the growing 
number of large electronic clinical records (Lee et al. 2008; Park et al. 2009; Blair et al. 2013). 
The genetic mechanisms underlying disease co-occurrences are being uncovered by 
means of increasingly powerful sequencing technologies. In particular, Genome-wide 
association studies (GWAS) are capable of revealing common risk variants that transcend 
traditional diagnostic boundaries. Examples include high correlations in genetics between 
migraine and stroke (Debette et al. 2015), and across psychiatric diseases such as schizophrenia, 
3major depressive disorder and bipolar disorder (Cross-Disorder Group of the Psychiatric 
Genomics Consortium et al. 2013). Causative mutations associated with multiple diseases have 
also been discovered through sequencing (Carvill et al. 2013). For example, SCN2A gene 
mutations were found to be associated not only with self-limited autosomal dominant syndrome 
of benign familial neonatal-infantile seizures but also epileptic encephalopathies (Liao et al. 
2010; Carvill et al. 2013). In similar vein, CACNA1A gene mutations have been implicated in 
a range of neurological conditions (Jouvenceau et al. 2001; Damaj et al. 2015; Subramanian et 
al. 2015).   
Obviously, shared genetic architecture across different diseases is suggestive of possible 
common genetic aetiologies. Disease interactions inferred from shared genes have often 
improved our understanding of the molecular mechanisms underlying inherited disease (Davis 
and Chawla 2011; Lechner et al. 2012). Moreover, shared genes have led directly to the 
identification of pan-cancer driver genes (Melamed et al. 2015) and the discovery of common 
genetic mechanisms of four neuropsychiatric disorders: autism spectrum disorder (ASD), 
epileptic encephalopathy, intellectual disability and schizophrenia (Li et al. 2016).  
However, sharing disease-causing genes does not automatically indicate the identity of 
the underlying molecular mechanisms because genes (and their protein products) have multiple 
functions and different mutations may impact different functions and cause different diseases. 
For example, many mutations in the PRKAR1A gene cause Carney complex due to decay of 
mRNA [HUIYING: do you mean nonsense-mediated mRNA decay due to frameshift and 
truncating variants?]  and the absence of protein translation (Kirschner et al. 2000) whereas 
another mutation in exon 11 (c.1101C→T) was found to cause acrodysostosis by truncating 
the last 14 amino acids in the coded cAMP-binding protein domain B protein due to the 
introduction of a stop codon (Linglart et al. 2011).  
4Meanwhile, the same genetic mutation can cause different heritable diseases. For 
example, the c.1932delC mutation in the HPS1 gene has been implicated in both Gitelman 
syndrome (Maki et al. 2004) and Hermansky–Pudlak syndrome (Wei et al. 2009). Similarly, 
the c.727-1G>T mutation in the KAL1 gene was found to be relevant to both diastrophic 
dysplasia (Barbosa et al. 2011) and renal agenesis (Tsai and Gill 2006), whilst another de novo
mutation (c.1267C>T) in the same gene has been reported to be associated with both epilepsy 
and ASD (Jiang et al. 2013).  When identical mutations are shared by different diseases, it 
suggests that these diseases share molecular mechanisms at least in part, for example the 
activation or deactivation of a specific function associated with the gene involved. Thus, shared 
mutations, rather than shared disease-causing genes, might be a more specific and hence more 
accurate indicator of genetic similarity between diseases. 
In this study, we identified disease relationships between inherited human diseases by 
ascertaining the number of shared genetic mutations. The disease-causing mutations were 
taken from the Human Gene Mutation Database (HGMD) (Stenson et al. 2017). The 
mutations relevant to the genetic diseases were added to the mutations associated with their 
‘sub-diseases’ as defined by the Human Phenotype Ontology project (HPO) (Kohler et al. 
2014). The resulting relationships identified between brain and psychiatric diseases are 
consistent with heritability-based studies, and related diseases identified by this mutation-
based approach share a significantly greater number of over-expressed genes than unrelated 
ones. The mutation-based approach was shown to be useful for the discovery of novel 
disease-causing mutations and for the identification of patients with Crohn’s disease. 
Moreover, the mutation-based disease network was shown to be consistent with phenotypic 
clusters. These results highlight the potential importance of using mutations to detect disease-
disease relationships. 
Results 
5Pairwise genetic similarity between human diseases 
We measured pairwise genetic similarity between two diseases according to the statistical 
significance of the sharing of disease-causing mutations as compared to random chance. This 
method was termed DRAM (Disease RelAtionship by shared Mutations). For comparison, we 
also mapped the mutations to genes, and assessed the genetic similarity according to the 
number of overlapping genes (namely DRAG, Disease RelAtionship by shared Genes).  
We assessed genetic disease-disease relations for a total of 42,083 disease pairs in 2,572 
diseases successfully mapped to Human Phenotype Ontology (HPO, see Methods). By using 
a binomial test P-value cutoff of 0.05, DRAM detected 17,514 related disease pairs (41.6%) 
involving 2,100 diseases (81.6%). This is somewhat fewer than the 25,692 related pairs 
yielded by the gene-based approach (DRAG). The smaller number of pairs of related diseases 
identified by the DRAM was as expected because sharing exactly the same mutation is a 
much stricter requirement than simply sharing the same gene. However, the disease-disease 
relationship ascertained from DRAM only moderately correlates with that from DRAG in 
terms of its significance (Spearman’s correlation coefficient (SPC) = 0.47, P-value is < 2.6 
×10-6).  The correlation is however slightly better (SPC=0.52) for related disease pairs from 
both DRAG and DRAM. If the most significant 17,514 pairs are selected [HUIYING: Why 
the most significant? Isn’t this the number of related disease pairs detected by DRAM?], the 
proportion of the pairs shared by both methods is only 60.7% (10,628/17,514), highlighting a 
significant difference between them in identifying related disease pairs.
Genetic correlation between brain disorders according to shared heritability and shared 
mutations 
To assess our methods, we compared disease relationships based upon shared mutations 
(DRAM) with those based upon shared genes (DRAG) as well as those based on shared 
6heritability (Anttila et al. 2016) in common brain diseases. As shown in Supplementary Figure 
S2, the correlation between heritability-based and mutation-based disease-disease relationships 
(from DRAM) is higher (SPC=0.505, P-value=2.5×10-4) than that from DRAG (0.343, P-
value=7.7×10-3). When an adjusted P-value cutoff of 1.0×10-3 (=0.05/48) was used, 22 and 12 
out of 48 pairs were detected as related by DRAM and the heritability-based estimation, 
respectively. Of the 12 most significantly related pairs by DRAM, 8 pairs overlapped with 
those obtained by the heritability-based approach (P-value < 1.0×10-3), which was a significant 
enrichment (P-value = 2.8×10-3) over pairs not showing relationships according to DRAM 
[HUIYING: Is this what you wanted to say?].  Meanwhile, DRAM discovered 13 related pairs 
that were not revealed by the heritability-based approach as listed in Table S1. 
Figure 1 depicts disease-disease relationships detected by both heritability and DRAM (in 
blue), by heritability only (in grey), and by DRAM only (in red) for 5 psychiatric diseases (in 
yellow) and 8 neurological diseases (in green). Six pairs of psychiatric diseases were connected 
based on either sharing of heritability (P-value threshold 0.05/48) or mutations (DRAM, P-
value threshold 0.05/48). For psychiatric diseases, DRAM only missed one connection between 
schizophrenia (SCZ) and ASD from heritability-based approach while indicating a mutation-
based connection between ADHD and ASD. For neurological diseases, all three pairs 
connected by sharing of heritability were also connected by mutations. DRAM, however, 
discovered four connections missed by the heritability-based approach. Those connections 
were Alzheimer disease and ischemic stroke, ischemic stroke and migraine, migraine with aura 
and ischemic stroke, and Parkinson disease and Alzheimer disease. More importantly, DRAM 
detected six connections between neurological and psychiatric diseases (P-value < 0.05/48) 
whereas the heritability-based approach only connected migraine with Major Depressive 
Disorder (MDD) and SCZ. As we shall see below in the Discussion, these disease relationships, 
7uncovered by DRAM but missed by the heritability-based approach, often share similar clinical 
phenotypes. 
Figure 1. Mutation-similarity network reveals relationships in brain diseases. Disease-disease 
relationship networks in eight neurological diseases (green nodes) and five psychiatric diseases (yellow 
nodes), assessed through sharing mutations by DRAM and sharing heritability in a previous study. The 
red edges connect disease pairs showing significant genetic similarity (P-value < 0.05/48, 1.0×10-3) by 
the DRAM method but not by heritability. The blue edges connect disease pairs showing genetic 
similarity by both methods (P-value < 0.05/48, 1.0×10-3). The grey edges connect disease pairs showing 
genetic similarity by heritability (P-value < 0.05/48, 1.0×10-3) but not by DRAM. F. Seizures stands for 
Focal seizures; G. Seizures - Generalized seizures; I. Stroke - Ischemic stroke; SCZ - Schizophrenia, 
BPD - Bipolar disorder, MDD - Major depressive disorder; ADHD - Attention deficit hyperactivity 
disorder; ASD - Autism spectrum disorder. 
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8If two diseases are related, it is reasonable to suppose that these diseases might share over-
expressed genes. We defined over-expressed genes using three different thresholds (5, 7 or 10-
fold higher than the average levels in all tissues as described in the Methods section). As shown 
in Table 1, 82%, 89% and 80% pairs in 45 related disease pairs detected by DRAM were found 
to share significantly more over-expressed genes than  under random expectation under three 
thresholds, respectively (all P-values<1.6×10-4 by binomial test). They were also significantly 
higher than 49%, 50% and 53% in 1363 unrelated disease pairs as defined by DRAM (P-
values<2×10-4).  
Table 1. Disease pairs with significant sharing of highly expressed genes (P-value ≤ 0.05) are 
enriched with pairs significantly sharing mutations. The enrichment is significantly higher than 
for the disease pairs sharing of genes. 
Mutations Genes
Threshold Significant a Not Significantb P-valuec Significantd P-valuee
5-fold 0.89 (40/45) 0.49 (673/1363) 1.9×10-8 0.52 (30/58) 1.310-7 
7-fold 0.82 (37/45) 0.50 (677/1363) 7.9×10-6 0.58 (33/58) 3.010-4 
10-fold 0.80 (36/45) 0.53 (723/1363) 1.6×10-4 0.54 (31/58) 2.010-4 
a Number of disease pairs with significant sharing of highly expressed genes and sharing of 
mutations divided by the total number of disease pairs with significant sharing of mutations (45 
pairs) only;
b Number of disease pairs with significant sharing of highly expressed genes but not significant 
sharing of mutations divided by total number of disease pairs without significant sharing of 
mutations (1363 pairs); 
c Binominal test results on difference between the number of disease pairs showing significant 
sharing of highly expressed genes among disease pairs significantly sharing mutations (DRAM)  
and the number of disease pairs showing significant sharing of highly expressed genes among 
disease pairs not significantly sharing mutations; 
d Number of disease pairs with significant sharing of highly expressed genes and sharing of genes 
in the total number of disease pairs with significant sharing of genes only (DRAG) (58 pairs);
e Binomial test results on difference between the number of disease pairs showing significant 
sharing of highly expressed genes among disease pairs significantly sharing mutations (DRAM) 
9Figure 2 shows disease-disease connections based on significant sharing of over-expressed 
genes and significant sharing of mutations. There are 62 disease pairs having significant 
sharing of over-expressed genes for any one of three thresholds, among which 45 pairs exhibit 
significant sharing of mutations. These diseases were color-coded according to the affected cell 
types (epithelial cells, nerve cells, Leydig cells, blood cells, embryonal cells, and muscle cells). 
As the Figure shows, disease-disease connections are not biased toward the same cell type. For 
example, the diseases affecting epithelial cells are shown sharing mutations with 31 diseases, 
19 of which are from the diseases not affecting epithelial cells. Eleven diseases affecting 
Leydig cells do not share mutations with any other disease affecting Leydig cells. In the Figure, 
the node size of a disease is proportional to the number of diseases that share mutations 
significantly with the node. Prostate cancer has the most (7) connections in sharing significant 
mutations with other diseases, and it also has 24 connections in terms of sharing a significant 
number of over-expressed genes. Thyroid carcinoma, squamous cell carcinoma, 
neuroectodermal neoplasm, muscular dystrophy, and leukemia, share significantly mutations 
with six other diseases. 
and the number of disease pairs showing significant sharing of highly expressed genes among 
disease pairs significantly sharing of genes (DRAG). 
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Figure 2. Disease pairs with significant sharing of over-expressed genes are enriched with disease pairs with 
significant sharing of mutations. Each node is a disease colour-coded in terms of its affected cell type. 62 disease 
pairs with significant sharing of over-expressed genes by 5-, 7-, or 10-fold are compared to the pairs with significant 
sharing of mutations. Larger nodes indicate a disease sharing mutations with more diseases. The thin edges represent 
disease pairs (only 17 pairs) not detected to be related (P-value > 0.05) by DRAM whereas the thick edges (45 pairs) 
represent disease pairs sharing over-expressed genes and mutations significantly at the same time. Different cell 
types affected by diseases were shown in different colours as labelled.
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As a comparison, DRAG identified 58 disease pairs as being related based on the same 
threshold (P ≤ 0.05) for defining disease-disease relationships. However, only 52%, 58% and 
54% of disease pairs were found to significantly share over-expressed genes according to the 
three thresholds for defining over-expression. These percentages are significantly lower than 
those yielded by DRAM (Table 1), but not significantly (with all P-values >0.1) different from 
the percentages in unrelated pairs as ascertained by DRAG (Table S2).  
Predicting novel mutations from mutations associated with relevant diseases
The ability to predict novel mutations by DRAM was compared to DRAG methods based either 
on the HGMD database or based on the DisGeneT database. As shown in Figure 3a, DRAM 
achieved the highest average MCC values for all diseases in ten-fold cross-validation. DRAG 
based on HGMD was found to exhibit higher performance than DRAG based on the DisGeneT 
database. This could be due to the fact that DisGeneT acquired gene-disease associations from 
multiple databases, which may be inconsistent with each other. Individually, DRAM achieved 
higher MCC values than DRAG (HGMD) in 248 out of 445 diseases (56%). It also achieved 
higher MCC values than DRAG (DisGeneT) in 313 (313/445, 70%) diseases. Application of 
the pairwise t-test indicated that these differences were significant (P-value=0.002 and 5.110-
6, respectively). This trend was confirmed by enrichment factors in top ranked predicted 
mutations (0.1%, 0.5% and 1% predictions) in Figure 3b. For example, DRAM represents an 
improvement over DRAG (HGMD) by 35% for enrichment factors for the top-ranked 0.1% 
predictions (Table 2). On average, DRAM has a sensitivity of 45.8% with a precision of 13.4% 
for all predicted mutations, as compared to 42.6% sensitivity and 12.6% precision by DRAG 
(HGMD), and 40.3% sensitivity and 13.1% precision by DRAG (DisGeneT). DRAM 
represents an improvement over DRAG (HGMD and DisGeneT) in terms of both sensitivity 
and precision. As a control, we examined the prediction by random sampling. Briefly, for each 
disease we randomly sampled the same number of predicted mutations by DRAM from HGMD, 
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and counted the number of mutations consistent with the known mutations relevant to the 
disease. As a result, the precision by random sampling was 0.483%, much lower than that by 
DRAM (13.4%).    
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Figure 3. Predicting disease-causing mutations by mutation (DRAM) or gene sharing (DRAG). Comparison of DRAM and DRAG
based on two datasets (HGMD and DisGeneT) by (a) the average Matthews correlation coefficient (MCC) and (b) average enrichment 
factors in top-ranked 0.1%, 0.5%, and 1% predicted mutations (across 445 diseases). The error bars are based on the standard error of the
[HUIYING: text missing?]mean.
14
Table 2. Predicting disease-causing mutations by applying genetic similarities across diseases 
according to sharing of mutations (DRAM) or genes (DRAMG) onto HGMD and DisGeneT 
datasets. The result is based on 10-fold cross-validation.
DRAM (HGMD)a DRAG (DisGeneT)b DRAG(HGMD)c
Sensitivityd 45.8% 40.3% 42.6%
Precisione 13.4% 13.1% 12.6%
0.1% EFf 244.1 133.8 181.3
0.5% EFg 77.5 50.2 72.2
1% EFh 71.9 45.7 69.6
a Genetic similarity defined by sharing mutations between diseases;
b Genetic similarity defined by sharing genes collected in DisGeneT database; 
c Genetic similarity defined by sharing genes assigned by mutations;  
d The average number of correctly predicted mutations divided by the number of  mutations in the 
test set;
e The average number of correctly predicted mutations divided by the average number of predicted 
mutations;
f Enrichment factor in top 0.1%; 
g Enrichment factor in top 0.5%; 
h Enrichment factor in top 1%.
As an example, the Peripheral Arterial Disease (PAD) was associated with 1307 
mutations according to HGMD. We randomly selected 1177 mutations (90%), by which 36 
diseases were found to exhibit significant sharing of mutations with PAD. These 36 related 
diseases contained 1367 unique mutations that were scored according to genetic similarity 
between these diseases with PAD (described in Method).  At the threshold with the maximum 
MCC (0.78), 114 mutations overlapped with the 130 remaining mutations, and 205 new 
mutations were predicted [HUIYING: what do you mean? Unclear!]. These new mutations 
were associated with 14 diseases as shown in Table S3. By comparison, DRAG (HGMD) and 
DRAG (DisGeneT) achieved MCC values of 0.63 and 0.22, respectively.
Identifying individuals susceptible to Crohn’s disease 
Although the overall precision in predicting novel mutations was only moderate, these 
predicted mutations are nevertheless useful for assisting disease diagnostics. To demonstrate 
this, we employed DRAM to identify individuals susceptible to Crohn’s disease by utilizing 
both the number of known Crohn’s disease-causing mutations listed in HGMD and the relation 
scores of mutations predicted from diseases relevant to Crohn’s disease[HUIYING: Unclear!]
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(see Methods). As shown in Figure 4, the gene-based approach, DRAG (HGMD) yielded 
essentially a random prediction with AUC=0.53, only slightly higher than the random selection 
(AUC=0.5). Relying on mutations from HGMD yields an AUC of 0.59.  A recently reported 
“Ensemble” method (Giollo et al. 2017), a meta-analytical method, achieved AUC of 0.66 for 
the same datasets. All of these AUC values are lower than 0.69 achieved by our method DRAM. 
When measured by the highest MCC values, DRAG (HGMD), HGMD and DRAM have MCC 
values of 0.17, 0.22, and 0.35, respectively. Meanwhile, 64 individuals susceptible to Crohn’s 
disease were predicted correctly (100%) by DRAM, as compared to 59 and 32 susceptible 
individuals predicted correctly by DRAG (92.1%) and HGMD (50%), respectively.   
Disease network according to DRAM
Figure 4. Receiver operating characteristic curves (ROC) for discriminating Crohn’s 
disease affecting from healthy individuals [HUIYING: what do you mean? Unclear!]by 
counting the number of known Crohn’s disease-related mutations in the HGMD directly,
by adding predicted mutations from DRAG, and from DRAM, as labelled. Dashed line 
indicates random prediction.
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To further examine the consistency between phenotype-based and mutation-based disease-
disease relations, we mapped diseases from human phenotype ontology (HPO ID) to the 
International Classification of Diseases (ICD-10 ID). Totally, 1611 out of 2572 HPO IDs 
were mapped to 19 “Chapter” IDs (clusters) of ICD-10. The mutation-based similarities of 
one ICD-10 cluster with another cluster or itself can be measured by calculating median –log 
Figure 5. The consistency between phenotypic and mutation-based clustering. There 
are 296 mutation-sharing disease connections (in grey) between 19 phenotypic chapters 
classified by ICD-10. Each node represents one disease phenotypic chapter detailed in 
Supplementary Table S5. The width of the edge represents the median –log(P) [P:
genetic similarity] between diseases within two chapters. The most significant 
association within a single chapter (in a loop) or between the chapters (in a line) is shown 
in red. 11 loops in red indicate the strongest association within the chapter itself. 
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(P-values) of all pairs of disease from two clusters. We found that most ICD-10 clusters (11 
out of 19 clusters) are likely to be similar to themselves in terms of mutation-based similarity 
(Detailed in Table S5 and Figure 5). In other words, in the majority of the cases, phenotypic 
classification was consistent with mutation-based classification. However, eight clusters are 
more similar to at least one other cluster than themselves (more details given in the 
Discussion).
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Discussion 
In this study, we systematically quantified genetic similarity across 2,572 human inherited 
diseases according to the extent of sharing of disease-causing mutations between diseases. This 
study was made possible by the availability of a comprehensive collection of disease-causing 
mutations represented by the HGMD and the hierarchical definitions of diseases by the HPO. 
We showed that disease-disease relations are more accurately described by shared specific 
mutations than by shared disease-causing genes based on multiple independent tests. This 
includes consistency with genetic correlation in brain diseases according to shared heritability, 
the sharing of over-expressed genes in different diseases, an improvement in predicting novel 
disease-causing mutations by ten-fold cross-validation, and more accurate discrimination of 
Crohn’s disease-susceptible individuals from healthy individuals.   
Shared genes are commonly employed for building disease-disease relationships. Inferring 
disease-disease relationships by shared mutations is a much stricter criterion than by shared 
genes. This is because shared mutations automatically imply shared genes, but not vice versa. 
As a result, shared genes will identify a larger number of related disease pairs. However, using 
a statistical test as a ranking tool allows us to identify significantly different related disease 
pairs. In fact, from the same number of top ranked pairs (17,514), only 60.7% are shared 
between DRAM and DRAG. This highlights the importance of using mutation-based inference, 
rather than gene-based inference, for revealing disease-disease associations. 
 We have demonstrated that DRAM is useful for identifying disease-disease relationships. 
When DRAM was applied to 13 brain diseases, a significant number of overlapping mutations 
was found between ASD and ADHD. This result is consistent with the observation that ADHD 
and ASD exhibit behavioural overlaps accompanied by abnormalities in similar brain systems 
(Lim et al. 2014; Polderman et al. 2014; Reilly et al. 2014). The similarities between diseases 
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as revealed by DRAM are also reflected in the overlap of their clinical features. For example, 
the relationship of ischemic strokes (I. Stroke) and migraine with aura identified by DRAM but 
missed by heritability, is consistent with the fact that ischemic strokes can be miscategorised 
as cerebral infarction during the course of a typical migraine with aura attack (Lee et al. 2016). 
The relationship between migraine and focal epilepsy concurs with the fact that both diseases 
can be associated with Cortical Spreading Depression (CSD), a wave of profound cellular 
depolarization (Rogawski 2012). Moreover, genetic similarity between Alzheimer disease and 
psychiatric diseases may reflect a shared cognitive effect spectrum. For example, major 
depressive disorder may be observed in the early stage of Alzheimer disease (Niida et al. 2013), 
and Alzheimer disease shares some of the same symptoms with late onset bipolar disorder 
(Lebert et al. 2008; Besga et al. 2015). Future studies that aim to connect both overlapping 
mutations and overlapping clinical features across genetically similar diseases could reveal 
additional insights into underlying molecular mechanisms.  
Another useful application of DRAM lies in its ability to disclose potential disease-causing 
mutations from the comparison of genetically related diseases. This is evident from the ten-
fold cross-validation using annotated disease-causing mutations in HGMD as well as the 
improved identification of Crohn’s disease-susceptible individuals through consideration of 
predicted disease-causing mutations. The overall low accuracy is likely because only a 
relatively small number of disease-causing mutations have so far been identified in the majority 
of heritable diseases. As more and more disease-causing mutations are discovered, we expect 
that DRAM will become even more powerful in uncovering both novel disease-disease 
relationships and disease-causing mutations, and therefore has the potential to aid disease 
diagnosis.  
We further tested the disease relationship by clustering diseases according to ICD-10 IDs, 
and built an association network of 19 disease chapters. The disease chapters of ICD-10 were 
20
based on the phenotypic characteristics of diseases (2010). We found that most disease clusters 
showed the closest relatedness with themselves based on shared mutations, which reflected 
consistency between the genetic and phenotypic similarity between diseases. On the other hand, 
the finding of eight phenotype clusters showing genetic similarity with other phenotypes 
suggests a shared genetic susceptibility, and hence could provide new information regarding 
the underlying biological mechanisms of these phenotypes by leveraging what is known about 
genetically similar phenotypes. We also examined disease-disease relationships at the level of 
individual diseases. If selected diseases containing at least nine associated diseases with a P-
value<1×10-6 (~0.05/40,000 [total number of disease pairs in the test]), 767 diseases (3,568 
pairs) from 14 disease clusters were involved. Figure S4 demonstrates how various diseases 
from different ICD-10 chapters connect with each other within and between chapters. The 
disease category with the highest number of connections is the Morphological abnormalities of 
the central nervous system” belonging to the “Congenital malformations, deformations and 
chromosomal abnormalities” cluster (shortened to “Congenital malformations, etc” in Figure 
S4). “Morphological abnormality of the central nervous system” has 62 connections within the 
chapter but 46 connections to diseases in other chapters. 
Methods 
HGMD dataset: We obtained 157,581 mutations [HUIYING: Causing human inherited 
disease? Associated with human inherited disease? In other words, did you use just the DMs 
or DM?s and polymorphic variants as well?] (including single base-pair substitutions and 
micro-insertions/deletions) from the Human Gene Mutation Database (HGMD Professional 
v.2015.4) (Stenson et al. 2017). In order to obtain a hierarchical definition of diseases, we 
mapped the “Cui” ID (defined by Unified Medical Language System, UMLS) of the diseases 
annotated in the HGMD into phenotypes as defined in the Human Phenotype Ontology (HPO) 
(Kohler et al. 2014). The HPO was downloaded from http://human-phenotype-
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ontology.github.io/downloads.html, including 11,785 HPO phenotypes. A total of 2,572 
diseases with 124,452 annotated mutations were mapped to HPO. The number of mutations 
associated with a disease ranges from 1 to as high as 20,685 for abnormalities of nervous 
system morphology, with an average of 16 mutations per disease and a median of 2. After 
including mutations assigned to subclasses of diseases, the average number increased to 48 and 
the median to 18. 
Brain disorders dataset: The genetic relationships of five psychiatric diseases and eight 
neurological diseases were obtained from a recent study carried out by the Brain Storm 
consortium (Anttila et al. 2016). These 13 diseases have 48 pairs sharing mutations in the 
HGMD database.  
DisGeNET dataset: In order to compare with a gene-based method, we downloaded the 
DisGeNET (Pinero et al. 2015), which collected associations between 15,093 phenotypes and 
17,381 genes by integrating several public data sources and literature, and clinical or abnormal 
human phenotypes. Of these, 11,103 disease phenotypes could be mapped to the HPO, and 927 
diseases were found to overlap with the diseases in the HGMD dataset. Because this dataset 
was to be used to assess our ability to predict associated mutations, we retained those diseases 
associated with >20 mutations; finally, 445 diseases remained. These diseases were associated 
with 14,085 genes from the DisGeNET, and 5102 genes harbouring 122,191 genetic mutations 
from the HGMD. 
Evaluating genetic similarity between diseases 
We evaluated genetic similarity between diseases by the number of shared mutations through 
the exact binominal test. Mutations were assigned to a disease if they associated either with the 
disease itself or its descendant phenotypes according to the hierarchical relationships of 
diseases. For two diseases that are associated with m mutations and n mutations, respectively, 
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the expected number of mutations shared by random chance is m*n/N, where N is the total 
number of mutations in the HGMD. We excluded pairs of diseases where one disease was a 
descendant of the other.  
Clustering diseases according to ICD-10 ID 
Diseases that shared mutations were mapped onto the disease clusters defined by ICD-10. ICD-
10 is the 10th version of the International Statistical Classification of Diseases and Related 
Health Problems (ICD), a medical classification list drawn up by the World Health 
Organization (WHO). ICD-10 contains 22 disease “Chapters” that are divided into 263 disease 
“blocks” and 12,131 disease “codes”. In this study, the HPO IDs were mapped to disease 
“Chapters”. 
Evaluating disease relations by cell-specific expression profiles  
The FANTOM5 (Lizio et al. 2015) human gene expression data cover a diverse range of 889 
cellular states and assess the promoter activity of every known gene in each cell or tissue type. 
We downloaded the human CAGE peak data qualified by transcripts per million (TMP) 
(http://fantom.gsc.riken.jp/5/datafiles/latest/extra/CAGE_peaks/hg19.cage_peak_tpm_ann.os
c.txt.gz). In this file, the terms describing cell types were queried in “Medical dictionary for 
Regular activity (MedDRA®)” to obtain “Cui” IDs that were subsequently mapped to HPO 
IDs, which led to 64 unique HPO IDs. The expression peaks assigned to each gene were 
averaged over multiple experiments for the same cell type, which yielded an estimated 
aggregate expression value for each gene in each cell type (disease). A gene was considered to 
be enriched in a single cell type if the gene expression was at least n (5, 7, or 10)-fold higher 
in that cell type than the average over all other cell types in the dataset (Yu et al. 2015). We 
defined genes enriched in a cell type as being over-expressed in that specific cell type (disease). 
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We measured disease relations according to the number of overlapping over-expressed genes 
in cells. For each pair of diseases, the expected number of overlapping over-expressed genes 
by chance would be m*n/N, where m and n are the numbers of over-expressed genes in two 
cell types, respectively; N is total number of genes (24,383, RefSeq gene information [hg19]) 
in the human genome (Zhao et al. 2016). The overexpression similarity was evaluated by the 
exact binomial test. 
Predicting novel mutations according to genetic similarity across diseases  
A cross-validation test was performed to assess how well disease-causing mutations from a 
particular disease can be inferred from known mutations associated with genetically similar 
diseases. For each query disease, we randomly divided all of its reported mutations into 10 
folds. Each time, nine folds of mutations were employed as training sets to calculate the 
genetic similarity with all other diseases. The score of a mutation in other diseases was 
calculated by using , where is a converted Chi-square with one degree of 
freedom from the P-value of a relevant disease i, and   is 1.0 only if mutation j is known to 
be associated with disease i, and is 0, otherwise. Mutations existing in the nine folds were 
excluded for testing. All mutations above a given threshold were predicted to be associated 
with the disease, whilst the others were not. The predicted disease-causing mutations were 
true positives (TP) if they appeared in the remaining fold and false positives (FP) if not; 
predicted non-disease-causing mutations were false negatives (FN) if they appeared in the 
test fold and true negatives (TN) if not. The schematic diagram for ten-fold cross-validation 
is shown in Figure S1. Performance was measured by sensitivity [SN=TP/(TP+FN)], 
precision [PR=TP/(TP+FP)], and the Matthews correlation coefficient [
 The threshold was individually optimized to maximise MCC 
for each fold of mutations per disease.  
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Additionally, we also calculated the enrichment factor (EF) in the top of all mutations:  
 , where  is the number of correctly predicted mutations in the top 
predicted mutations in the test fold, is the number of predicted mutations in the top 
scored mutations, is the number of mutations in the test fold relevant to a disease; 
and is the total number of mutations in the HGMD dataset. 
Discriminating Crohn’s disease-susceptible individuals from healthy persons 
We further utilized the mutation-based genetic similarity approach to identify Crohn’s disease-
susceptible individuals. The whole exome sequencing data in VCF format of 111 persons was 
downloaded from Critical Assessment of Genome Interpretation (CAGI). These samples were 
derived from 47 healthy individuals and 64 individuals who were affected by Crohn’s disease. 
For each individual, we counted the number (N) of harboured mutations considered to be 
relevant to Crohn’s disease according to the HGMD. We also employed mutations predicted 
as being relevant to Crohn’s disease by DRAM as described in the section above. The final 
disease susceptibility score by D-score= , where Si represents the predicted Chi-
square statistics for novel Crohn’s disease-related mutations, and w is a normalisation factor 
determined by trial and error (w=30). All putatively neutral mutations were removed by 
excluding those mutations with a minor allele frequency >0.01 in the Exome Sequencing 
Project (ESP) (http://evs.gs.washington.edu/EVS/). The performance of each method was 
assessed by the Area Under the receiver operating characteristic Curve (AUC).
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